In September 2013, the FDA produced new labeling recommendations for lengthy acting and prolonged launch opioids necessitating manufacturers to eliminate reasonable suffering as indication to be used, instead stating the drug is for "ache severe more than enough to require daily, all over-the-clock, lasting opioid therapy".Sadly, your browser just